SCHEMBL17882288

SCHEMBL17882288

CCC(C)(C)C(=O)N(CCO)Cc1cc(F)cc(F)c1F

nearest known ligand 0.68

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 20/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29912684 1.00 RIPK1 (0.68) RIPK1
SCHEMBL29638052 0.81 RIPK1 (1.00) RIPK1
SCHEMBL29912920 0.81 RIPK1 (1.00) RIPK1
SCHEMBL17882381 0.81 RIPK1 (1.00) RIPK1
SCHEMBL17874115 0.81 RIPK1 (1.00) RIPK1
SCHEMBL19448788 0.78 RIPK1 (0.70) RIPK1
SCHEMBL14013300 0.75 RIPK1 (0.46) RIPK1
SCHEMBL17882243 0.72 RIPK1 (0.73) RIPK1
SCHEMBL14013780 0.72 RIPK1 (0.43) RIPK1
SCHEMBL17882413 0.71 RIPK1 (1.00) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224237-B1 NECROSIS INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2024-09-11 — — EP disclosed
CN-115197098-A Cell necrosis inhibitor 北京生命科学研究所 2022-10-18 — — CN disclosed
CN-107108467-B Cell necrosis inhibitor 北京生命科学研究所 2022-08-19 — — CN disclosed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US disclosed
US-10682319-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-16 — — US disclosed
US-10682319-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-16 — — US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US disclosed
US-20180263934-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-09-20 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
WO-2016101885-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10682319-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL RIPK1 2/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL RIPK1 2/4885
US-20170290790-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885
US-20180263934-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback